HB2350 EngrossedLRB103 26427 BMS 52790 b HB2350 Engrossed LRB103 26427 BMS 52790 b
HB2350 Engrossed LRB103 26427 BMS 52790 b
1 AN ACT concerning regulation.
2 Be it enacted by the People of the State of Illinois,
3 represented in the General Assembly:
4 Section 5. The Illinois Insurance Code is amended by
5 changing Section 356u as follows:
6 (215 ILCS 5/356u)
7 Sec. 356u. Pap tests and prostate cancer screenings.
8 (a) A group policy of accident and health insurance that
9 provides coverage for hospital or medical treatment or
10 services for illness on an expense-incurred basis and is
11 amended, delivered, issued, or renewed after January 1, 2024
12 shall provide coverage, without imposing a deductible,
13 coinsurance, copayment, or any other cost-sharing requirement,
14 for all of the following:
15 (1) An annual cervical smear or Pap smear test for all
16 female insureds.
17 (2) An annual prostate cancer screening for male
18 insureds upon the recommendation of a physician licensed
19 to practice medicine in all its branches for:
20 (A) asymptomatic individuals men age 50 and over;
21 (B) African-American individuals men age 40 and
22 over; and
23 (C) individuals men age 40 and over with a family
HB2350 Engrossed LRB103 26427 BMS 52790 b
HB2350 Engrossed- 2 -LRB103 26427 BMS 52790 b HB2350 Engrossed - 2 - LRB103 26427 BMS 52790 b
HB2350 Engrossed - 2 - LRB103 26427 BMS 52790 b
1 history of or genetic predisposition to prostate
2 cancer.
3 (3) Surveillance tests for ovarian cancer for female
4 insureds who are at risk for ovarian cancer.
5 (b) This Section shall not apply to agreements, contracts,
6 or policies that provide coverage for a specified disease or
7 other limited benefit coverage.
8 (c) This Section does not apply to coverage of prostate
9 cancer screenings to the extent such coverage would disqualify
10 a high-deductible health plan from eligibility for a health
11 savings account pursuant to Section 223 of the Internal
12 Revenue Code.
13 (d) For the purposes of this Section:
14 "At risk for ovarian cancer" means:
15 (1) having a family history (i) with one or more
16 first-degree relatives with ovarian cancer, (ii) of
17 clusters of women relatives with breast cancer, or (iii)
18 of nonpolyposis colorectal cancer; or
19 (2) testing positive for BRCA1 or BRCA2 mutations.
20 "Prostate cancer screening" means medically viable methods
21 for the detection and diagnosis of prostate cancer, including
22 a digital rectal exam and the prostate-specific antigen test
23 and associated laboratory work. "Prostate cancer screening"
24 includes medically necessary subsequent follow-up testing as
25 directed by a health care provider, including, but not limited
26 to:
HB2350 Engrossed - 2 - LRB103 26427 BMS 52790 b
HB2350 Engrossed- 3 -LRB103 26427 BMS 52790 b HB2350 Engrossed - 3 - LRB103 26427 BMS 52790 b
HB2350 Engrossed - 3 - LRB103 26427 BMS 52790 b
1 (1) urinary analysis;
2 (2) serum biomarkers; and
3 (3) medical imaging, including, but not limited to,
4 magnetic resonance imaging.
5 "Surveillance tests for ovarian cancer" means annual
6 screening using (i) CA-125 serum tumor marker testing, (ii)
7 transvaginal ultrasound, (iii) pelvic examination.
8 (Source: P.A. 102-1073, eff. 1-1-23.)
9 Section 99. Effective date. This Act takes effect January
10 1, 2025.
HB2350 Engrossed - 3 - LRB103 26427 BMS 52790 b